NASDAQ:NMTR - 9 Meters Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.71
  • Forecasted Upside: 249.21 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$1.35
▼ -0.03 (-2.17%)

This chart shows the closing price for NMTR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 9 Meters Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NMTR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NMTR

Analyst Price Target is $4.71
▲ +249.21% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for 9 Meters Biopharma in the last 3 months. The average price target is $4.71, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 249.21% upside from the last price of $1.35.

This chart shows the closing price for NMTR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in 9 Meters Biopharma. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/25/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/24/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated CoverageBuy$3.00Medium
6/4/2021CitigroupInitiated CoverageBuyMedium
3/25/2021Brookline Capital ManagementReiterated RatingBuyHigh
3/25/2021Brookline Capital AcquisitionReiterated RatingBuy$6.00Medium
3/25/2021Maxim GroupInitiated CoverageBuy$3.00Medium
1/28/2021OppenheimerInitiated CoverageOutperform$6.00High
1/5/2021William BlairReiterated RatingBuyN/A
10/30/2020Maxim GroupInitiated CoverageBuyMedium
9/24/2020William BlairReiterated RatingBuyMedium
9/23/2020William BlairInitiated CoverageOutperform$5.00High
9/21/2020HC WainwrightReiterated RatingBuyLow
8/18/2020Brookline Capital ManagementInitiated CoverageBuy$5.00High
6/30/2020SunTrust BanksInitiated CoverageBuy$5.00High
10/11/2018Raymond JamesInitiated CoverageMarket PerformN/A
10/10/2016(FBRC)Initiated CoverageMarket PerformN/A
(Data available from 6/23/2016 forward)
9 Meters Biopharma logo
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on patients with rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS) and celiac disease, as well as for undisclosed rare diseases and/or unmet needs. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease; and NM-002, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that is in Phase 2 clinical trial to treat SBS. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. 9 Meters Biopharma, Inc. has a collaboration with the Duke Clinical Research Institute to support the clinical development of NM-002. The company is headquartered in Raleigh, North Carolina.
Read More

Today's Range

Now: $1.35
Low: $1.34
High: $1.40

50 Day Range

MA: $1.25
Low: $1.04
High: $1.50

52 Week Range

Now: $1.35
Low: $0.45
High: $2.26

Volume

2,830,304 shs

Average Volume

7,590,851 shs

Market Capitalization

$339.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of 9 Meters Biopharma?

The following Wall Street analysts have issued stock ratings on 9 Meters Biopharma in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Maxim Group, Oppenheimer Holdings Inc., SunTrust Banks, Inc., William Blair, and Zacks Investment Research.
View the latest analyst ratings for NMTR.

What is the current price target for 9 Meters Biopharma?

7 Wall Street analysts have set twelve-month price targets for 9 Meters Biopharma in the last year. Their average twelve-month price target is $4.71, suggesting a possible upside of 250.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting NMTR will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for 9 Meters Biopharma in the next year.
View the latest price targets for NMTR.

What is the current consensus analyst rating for 9 Meters Biopharma?

9 Meters Biopharma currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NMTR will outperform the market and that investors should add to their positions of 9 Meters Biopharma.
View the latest ratings for NMTR.

What other companies compete with 9 Meters Biopharma?

How do I contact 9 Meters Biopharma's investor relations team?

9 Meters Biopharma's physical mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company's listed phone number is 919-275-1933 and its investor relations email address is [email protected] The official website for 9 Meters Biopharma is www.9meters.com.